Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Moderna, Inc is a biotechnology business based in the US. Moderna shares (MRNA) are listed on the NASDAQ and all prices are listed in US Dollars. Moderna employs 975 staff and has a trailing 12-month revenue of around USD$105.8 million.
Since the stock market crash in March caused by coronavirus, Moderna's share price has had significant positive movement.
Its last market close was USD$59.15, which is 69.18% up on its pre-crash value of USD$18.23 and 230.26% up on the lowest point reached during the March crash when the shares fell as low as USD$17.91.
If you had bought USD$1,000 worth of Moderna shares at the start of February 2020, those shares would have been worth USD$1,303.79 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$2,902.49.
|Latest market close||USD$59.15|
|52-week range||USD$13.53 - USD$95.21|
|50-day moving average||USD$69.0897|
|200-day moving average||USD$55.1863|
|Wall St. target price||USD$92.31|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.348|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-09-11)||-0.32%|
|1 month (2020-08-18)||-11.76%|
|3 months (2020-06-18)||-8.93%|
|6 months (2020-03-18)||87.30%|
|1 year (2019-09-18)||232.68%|
|2 years (2018-09-14)||N/A|
|3 years (2017-09-14)||N/A|
|5 years (2015-09-14)||N/A|
|Revenue TTM||USD$105.8 million|
|Gross profit TTM||USD$-436,100,000|
|Return on assets TTM||-12.41%|
|Return on equity TTM||-22.75%|
|Market capitalisation||USD$23.4 billion|
TTM: trailing 12 months
There are currently 22.9 million Moderna shares held short by investors – that's known as Moderna's "short interest". This figure is 14.4% up from 20.0 million last month.
There are a few different ways that this level of interest in shorting Moderna shares can be evaluated.
Moderna's "short interest ratio" (SIR) is the quantity of Moderna shares currently shorted divided by the average quantity of Moderna shares traded daily (recently around 11.3 million). Moderna's SIR currently stands at 2.02. In other words for every 100,000 Moderna shares traded daily on the market, roughly 2020 shares are currently held short.
However Moderna's short interest can also be evaluated against the total number of Moderna shares, or, against the total number of tradable Moderna shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moderna's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Moderna shares in existence, roughly 70 shares are currently held short) or 0.0925% of the tradable shares (for every 100,000 tradable Moderna shares, roughly 93 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Moderna.
Find out more about how you can short Moderna stock.
We're not expecting Moderna to pay a dividend over the next 12 months.
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.